X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AJANTA PHARMA Fact Sheet, AJANTA PHARMA Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA Fact Sheet   (AJPH)

Here is the latest financial fact sheet of AJANTA PHARMA. For more details, see the AJANTA PHARMA quarterly results and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

AJANTA PHARMA Price History

Price Rs 1,351.5
Mkt Cap Rs m 118,860
Vol '000 7.9
P/E X 24.6
P/CF X 26.6
EPS (TTM) Rs 55.0
% ch % -0.3
No. of shares m 87.95
% ch week % -3.9
% ch 1-mth % -14.8
% ch 12-mth % -21.1
52 week H/L Rs 1,870.0/1,106.0
(As on Feb 22, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

AJANTA PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
AJANTA PHARMA EQUITY SHARE DATA
High Rs4926981,1777791,720 
Low Rs2012316252991,103 
Sales per share (Unadj.) Rs571.2392.4340.8166.1194.6 
Earnings per share (Unadj.) Rs65.247.366.034.945.2 
Diluted earnings per shareRs8.812.726.635.245.6 
Cash flow per share (Unadj.) Rs92.061.778.340.850.3 
Dividends per share (Unadj.) Rs7.506.2510.006.008.00 
Adj. dividends per shareRs1.011.694.036.058.07 
Dividend yield (eoy) %2.21.31.11.10.6 
Book value per share (Unadj.) Rs251.3165.9167.394.8132.0 
Adj. book value per shareRs33.944.767.595.6133.3 
Shares outstanding (eoy) m11.8623.7235.4688.7188.77 
Bonus/Rights/Conversions  -FV5B1:2,ESOSFV2- 
Price / Sales ratio x0.61.22.63.27.3 
Avg P/E ratio x5.39.813.715.431.2 
P/CF ratio (eoy) x3.87.511.513.228.1 
Price / Book Value ratio x1.42.85.45.710.7 
Dividend payout %11.513.215.217.217.7 
Avg Mkt Cap Rs m4,10911,02131,95147,797125,299 
No. of employees `000NANANANANA 
Total wages/salary Rs m9381,2321,5702,0062,570 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
AJANTA PHARMA INCOME DATA
Net Sales Rs m6,7749,30812,08314,73617,275 
Other income Rs m6256137168166 
Total revenues Rs m6,8369,36412,22114,90417,442 
Gross profit Rs m1,3202,2453,6885,0525,807 
Depreciation Rs m319342439516451 
Interest Rs m154191875949 
Profit before tax Rs m9101,7683,2994,6455,474 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m000-850 
Tax Rs m1376479601,4621,460 
Profit after tax Rs m7731,1212,3393,0994,014 
Gross profit margin %19.524.130.534.333.6 
Effective tax rate %15.136.629.131.526.7 
Net profit margin %11.412.019.421.023.2 
AJANTA PHARMA BALANCE SHEET DATA
Current assets Rs m3,3973,6905,2016,3347,639 
Current liabilities Rs m2,5022,2232,7542,4962,715 
Net working cap to sales %13.215.820.226.028.5 
Current ratio x1.41.71.92.52.8 
Inventory Days Days9058473943 
Debtors Days Days7659616479 
Net fixed assets Rs m2,4862,8513,7294,5836,914 
Share capital Rs m118118177177177 
"Free" reserves Rs m2,8253,7745,6508,18611,442 
Net worth Rs m2,9803,9345,9338,41111,721 
Long term debt Rs m761733523333149 
Total assets Rs m6,4887,1829,49411,46414,814 
Interest coverage x6.910.238.879.5112.9 
Debt to equity ratio x0.30.20.100 
Sales to assets ratio x1.01.31.31.31.2 
Return on assets %14.318.325.627.527.4 
Return on equity %25.928.539.436.834.2 
Return on capital %28.442.052.452.846.5 
Exports to sales %50.654.454.754.755.1 
Imports to sales %5.65.65.04.46.0 
Exports (fob) Rs m3,4275,0676,6068,0629,527 
Imports (cif) Rs m3775246026531,038 
Fx inflow Rs m3,5485,3336,8968,49410,422 
Fx outflow Rs m6809351,1681,2471,678 
Net fx Rs m2,8684,3995,7287,2478,744 
AJANTA PHARMA CASH FLOW
From Operations Rs m 704 2,343 2,124 2,794 3,264 
From Investments Rs m -531 -1,037 -1,878 -1,584 -2,093 
From Financial Activity Rs m -128 -1,045 -201 -1,052 -1,186 
Net Cashflow Rs m 44 261 45 159 -15 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 73.8%
Foreign collaborators 0.0%
Indian inst/Mut Fund 1.6%
FIIs 7.6%
ADR/GDR 0.0%
Free float 17.0%
Shareholders 20,968
Pledged promoter(s) holding 4.4%
 

Company Information

REGD OFF Ajanta House, Charkop, Kandivli (W), Mumbai - 400 067
E-MAIL deodatta.pandit@ajantapharma.com WEB www.ajantapharma.com
TELEPHONE (022) 66061000 FAX (022) 6606 1200
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Kapoor & Parekh Assoc.
CHM: Mannalal B. Agrawal COMP SEC: Gaurang Shah YEAR OF INC: 1979 BSE CODE: 532331 FV (Rs): 5 DIV YIELD (%): 0.6

More Pharmaceuticals Company Fact Sheets:   INDRAPRASTHA MEDICAL  FULFORD INDIA  BIOCON LTD  NATCO PHARMA  GLENMARK PHARMA  

Compare AJANTA PHARMA With:   INDRAPRASTHA MEDICAL  FULFORD INDIA  BIOCON LTD  NATCO PHARMA  GLENMARK PHARMA  

Compare AJANTA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AJANTA PHARMA

AJANTA PHARMA - ADCOCK INGRAM COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS